32 results
6-K
EX-99.2
PBM
Psyence Biomedical Ltd. Warrant
20 Sep 24
Share Purchase and Sale Agreement
5:00pm
Use Disorders, we will look to PsyLabs for consistent supply of high-purity, nature-derived psilocybin that will best position us for long-term success
6-K
EX-99.1
PBM
Psyence Biomedical Ltd. Warrant
30 Aug 24
Current report (foreign)
4:06pm
Screening Day -28 to Day -2 Long Term Follow Up (3-month post week 10) Responders Non-Responders Cohort 2 10mg PEX010 29 subjects Cohort 3 1mg PEX010 29 … subjects Additional PAP cycle (repeat visits 5-11) All non-responders will be offered PAP with 25mg PEX010 Long Term Follow Up (3 months post week 10
424B3
PBM
Psyence Biomedical Ltd. Warrant
30 Aug 24
Prospectus supplement
4:00pm
short-term and long-term, will depend on many factors, including, but not limited:
the time and cost necessary to complete ongoing and planned … require Psyence to incur non-recurring and other charges, increase Psyence’s near and long-term expenditures, issue securities that dilute Psyence’s
F-1
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Registration statement (foreign)
4:07pm
, and Psyence may need to seek additional funds sooner than planned. Psyence’s future funding requirements, both short-term and long-term, will depend … its existing business. Any of these relationships may require Psyence to incur non-recurring and other charges, increase Psyence’s near and long-term expenditures
424B3
PBM
Psyence Biomedical Ltd. Warrant
19 Aug 24
Prospectus supplement
9:27am
requirements, both short-term and long-term, will depend on many factors, including, but not limited:
the time and cost necessary to complete ongoing … of these relationships may require Psyence to incur non-recurring and other charges, increase Psyence’s near and long-term expenditures, issue securities that dilute
POS AM
b6i 8lcq1rvuizvk1d23
12 Aug 24
Prospectus update (post-effective amendment)
5:23pm
6-K
EX-99.4
dopjg9uujl0 fkrnlese
24 Jul 24
Current report (foreign)
4:35pm
6-K
EX-4.2
i61l9c kd
23 Jul 24
Current report (foreign)
4:05pm
6-K
EX-4.2
h2hii
20 Jun 24
Current report (foreign)
4:10pm
6-K
EX-4.2
6533elctp9dq8kt
6 Jun 24
Current report (foreign)
8:00am
F-1/A
l4n2i0x6
6 May 24
Registration statement (foreign) (amended)
8:27pm
F-1/A
w2r1144a o3ch5
18 Apr 24
Registration statement (foreign) (amended)
6:03am
6-K
EX-99.2
k0la5x5c
12 Mar 24
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
5:25pm
6-K
EX-99.3
iq071dmjr8x qv3
12 Mar 24
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
5:25pm